ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Effect of concomitant antibiotics use on patient outcomes and adverse effects in patients treated with ICIs

Yu, Jiuhang; Yin, Yichuang; Yu, Yang; Cheng, Mengfei; Zhang, Shuo; Jiang, Shuai*; Dong, Mei*哈尔滨医科大学
Immunopharmacology and Immunotoxicology2023-5-4DOI: 10.1080/08923973.2022.2145966
3被引6阅读
引用收藏
分享

摘要

Background: Immune checkpoint inhibitors (ICIs) such as PD-1/PD-L1/CTLA-4 inhibitors have brought new opportunities for the cure of cancer patients and have been widely used and which are the most successful cancer immunotherapy drug in recent years. Gut microbiome and metabolites exert a critical regulatory function in cancer immunotherapy of ICIs, which can be affected by antibiotics intervention. However, inflammatory infections caused by impaired immune function in tumor patients often require antibiotic treatment. Objective: In this review, we briefly discussed the correlation between antibiotics and ICIs treatment to evaluate the impact of antibiotics on cancer progression. Methods: By searches of PubMed, we collected the data such as progression-free survival time (PFS) and overall survival time (OS) in patients with non-small cell lung cancer (NSCLC), kidney cancer, Melanoma, colorectal cancer, and other tumors. Results: Antibiotics have a negative effect on the prolongation of survival in cancer patients treated with ICIs. This may depend on the patient's cancer type and the type of ICIs and antibiotics they have used. Conclusions: Antibiotics may reduce the effectiveness of immunotherapy by depleting the body's microbiome. Therefore, paying attention to the changes in the level of microorganisms in cancer patients, while making more individualized and precise improvements in treatment regimens, may bring new opportunities to improve the efficacy of immunotherapy.

学科与关键词

关键词
Antibioticsimmune checkpoint inhibitorstumorsmicrobiotacancer immune therapy
相关
加载中…
  • Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
    Jiang, Shuai; Geng, Shuai; Chen, Qian; Zhang, Chen; Cheng, Mengfei; Yu, Yang; Zhang, Shuo; Shi, Ning*; Dong, Mei*Frontiers in Oncology, 2022, 12: 823705.被引 15
  • The negative effect of concomitant medications on immunotherapy in non-small cell lung cancer: An umbrella review
    Chen, Jixin; Chen, Shuqi; Luo, Huiyan; Long, Shunqin; Yang, Xiaobing; He, Wenfeng; Wu, Wanyin*; Wang, Sumei*International Immunopharmacology, 2023, 124: 110919.被引 1
  • Gold digging: Searching for gut microbiota that enhances antitumor immunity
    Hou, Fengyi; Pan, Zhiyuan; Yang, Ruifu; Zhi, Fachao*; Bi, Yujing*Journal of Cellular Physiology, 2021, 236(8): 5495-5511.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Immunopharmacology and Immunotoxicology
发表日期
2023-05-04
卷期
第 45 卷, 第 3 期
页码
386-394
DOI
10.1080/08923973.2022.2145966
语言
ENGLISH
成果收录
SCIE
资助标注
Project of Beijing Medical Award Foundation [YXJL-2022-0187-0013]; Beijing Hongdingxiang Public Welfare Development Center [BJ-HDX-20220437]

作者

  • Y

    Yu, Jiuhang (第一作者)

    harbin med univ · jiamusi univ

  • Y

    Yin, Yichuang

    harbin med univ · jiamusi univ

查看全部 7 位作者收起作者
  • Y

    Yu, Yang

    harbin med univ

  • C

    Cheng, Mengfei

    harbin med univ

  • Z

    Zhang, Shuo

    harbin med univ

  • J

    Jiang, Shuai (通讯)

    harbin med univ

  • D

    Dong, Mei (通讯)

    harbin med univ · jiamusi univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417